A Gene Therapy journal preclinical study reported that gene augmentation reversed complete congenital stationary night blindness in mouse models. The work targeted complete cCSNB, a condition where retinal circuitry fails to generate reliable visual responses from birth. In the treated animals, researchers reported improvements in both retinal functionality and downstream visual performance measures. The results add preclinical support for gene-based strategies in severe inherited retinal disorders where options remain limited. While translation to humans is not established, the study strengthens the rationale for advancing similar augmentation approaches toward further safety and dosing optimization.